Galmed Pharmaceuticals ( (GLMD) ) has issued an announcement.
On March 20, 2025, Galmed Pharmaceuticals announced the grant of a new patent extending the protection of its lead compound, Aramchol, to 2039. This patent covers a combination therapy of Aramchol and Resmetirom for treating NASH, positioning Galmed at the forefront of combination therapies in this field. The patent is a significant milestone, providing Galmed with a 15-year exclusivity period to capitalize on Aramchol’s commercial potential. The NASH treatment market is projected to grow significantly, and Galmed’s strategy of combining Aramchol with complementary agents aims to address the complex pathologies of NASH effectively. This move strengthens Galmed’s intellectual property portfolio and enhances its strategic flexibility for future commercialization and partnerships.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for liver and fibro-inflammatory diseases. The company primarily focuses on Aramchol for the treatment of non-alcoholic steatohepatitis (NASH) and other liver-related conditions. Additionally, Galmed is collaborating with the Hebrew University on developing Amilo-5MER, a synthetic peptide.
YTD Price Performance: -31.93%
Average Trading Volume: 898,489
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $4.16M
See more insights into GLMD stock on TipRanks’ Stock Analysis page.